{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:10:26Z","timestamp":1781478626947,"version":"3.54.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.contraception.2008.10.017","type":"journal-article","created":{"date-parts":[[2009,1,19]],"date-time":"2009-01-19T09:10:26Z","timestamp":1232356226000},"page":"272-281","source":"Crossref","is-referenced-by-count":33,"title":["Profile of the progesterone derivative chlormadinone acetate \u2014 Pharmocodynamic properties and therapeutic applications"],"prefix":"10.1016","volume":"79","author":[{"given":"Ren\u00e9","family":"Druckmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2008.10.017_bib1","doi-asserted-by":"crossref","first-page":"7940","DOI":"10.1073\/pnas.122225699","article-title":"Coactivator\/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486","volume":"99","author":"Liu","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.contraception.2008.10.017_bib2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2165\/00003495-199651020-00002","article-title":"Comparative pharmacology of newer progestogens","volume":"51","author":"Kuhl","year":"1996","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.contraception.2008.10.017_bib3","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.maturitas.2003.09.014","article-title":"Classification and pharmacology of progestins","volume":"46","author":"Schindler","year":"2003","journal-title":"Maturitas"},{"key":"10.1016\/j.contraception.2008.10.017_bib4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1020072325818","article-title":"Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception","volume":"3","author":"Stanczyk","year":"2002","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.contraception.2008.10.017_bib5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0301-2115(03)00156-8","article-title":"A randomised comparison of side effects and patient inconvenience of two vaginal progesterone formulations used for luteal support in in vitro fertilisation cycles","volume":"111","author":"Ng","year":"2003","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.contraception.2008.10.017_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09513590400020880","article-title":"Evaluation of the effects of various gestagens on insulin sensitivity, using homeostatic model assessment, in postmenopausal women on hormone replacement therapy","volume":"20","author":"Dansuk","year":"2005","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.contraception.2008.10.017_bib7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/00042192-200310020-00010","article-title":"Comparison of the difference in histopathology and cell cycle kinetics among the postmenopausal endometrium treated with different progestins in sequential-combined hormone replacement therapy","volume":"10","author":"Chang","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.contraception.2008.10.017_bib8","first-page":"96","article-title":"Uses of progesterone in clinical practice","volume":"44","author":"Warren","year":"1999","journal-title":"Int J Fertil Women's Med"},{"key":"10.1016\/j.contraception.2008.10.017_bib9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0378-5122(01)00170-0","article-title":"Chlormadinone acetate versus micronized progesterone in the sequential combined hormone replacement therapy of the menopause","volume":"40","author":"Pelissier","year":"2001","journal-title":"Maturitas"},{"key":"10.1016\/j.contraception.2008.10.017_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0010-7824(90)90106-6","article-title":"Cyproterone acetate\/ethinyl estradiol in the treatment of acne. A comparative dose\u2013response study of the estrogen component","volume":"42","author":"Fug\u00e8re","year":"1990","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2008.10.017_bib11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/BF03350769","article-title":"Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism","volume":"21","author":"Sahin","year":"1998","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.contraception.2008.10.017_bib12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000292281","article-title":"An open randomized comparative study of an oral contraceptive containing ethinyl estradiol and cyproterone acetate with and without the GnRH analogue goserelin in the long-term treatment of hirsutism","volume":"41","author":"Vegetti","year":"1996","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.contraception.2008.10.017_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13625180701300194","article-title":"Combined hormonal contraception and venous thromboembolism","volume":"12","author":"Martinez","year":"2007","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2008.10.017_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/13625189909040809","article-title":"A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel","volume":"4","author":"Winkler","year":"1999","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2008.10.017_bib15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.contraception.2007.07.002","article-title":"Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents","volume":"76","author":"Sabatini","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2008.10.017_bib16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000051701","article-title":"Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE\/CMA (Belara) and EE\/LNG (Microgynon)","volume":"203","author":"Worret","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.contraception.2008.10.017_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/09513590701214414","article-title":"Antiandrogenic activity of norgestimate in a human androgen-dependent stable-transfected cell line","volume":"23","author":"Paris","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.contraception.2008.10.017_bib18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000068893","article-title":"Clinical evidence of the endocrinological influence of a triphasic oral contraceptive containing norgestimate and ethinyl estradiol in treating women with acne vulgaris. A pilot study","volume":"206","author":"Sator","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.contraception.2008.10.017_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.contraception.2005.07.010","article-title":"Treating acne with oral contraceptives: use of lower doses","volume":"73","author":"Huber","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2008.10.017_bib20","first-page":"1","article-title":"Oral contraceptives in the treatment of acne","volume":"6","author":"Tan","year":"2001","journal-title":"Skin Therapy Lett"},{"issue":"Suppl 1","key":"10.1016\/j.contraception.2008.10.017_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/09513590701585045","article-title":"Long-term use of progestogens \u2014 getting the balance right: Molecular biology and the endometrium","volume":"23","author":"Druckmann","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.contraception.2008.10.017_bib22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/01.AOG.0000154152.12088.48","article-title":"Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer","volume":"105","author":"Greer","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2008.10.017_bib23","series-title":"Pharmakologie der Gestagene","first-page":"28","author":"Kuhl","year":"1999"},{"key":"10.1016\/j.contraception.2008.10.017_bib24","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00003495-200363050-00003","article-title":"Progestogens with antiandrogenic properties","volume":"63","author":"Raudrant","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.contraception.2008.10.017_bib25","series-title":"Chlormadinonacetat bei Androgenisieringserscheinungen","first-page":"1","article-title":"Chemie und Pharmakologie von Chlormadinonacetat","author":"Kuhl","year":"1995"},{"key":"10.1016\/j.contraception.2008.10.017_bib26","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/acta.0.0630705","article-title":"Effects of continuous daily administration of 0.5 mg of chlormadinone acetate on the plasma levels of progesterone and on the urinary excretion of luteinizing hormone and total oestrogens","volume":"63","author":"Larsson-Cohn","year":"1970","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.contraception.2008.10.017_bib27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0015-0282(16)38227-9","article-title":"Effect of daily administration of 0.5 mg. of chlormadinone acetate on plasma levels of follicle-stimulating hormone, luteinizing hormone, and progesterone during the menstrual cycle","volume":"22","author":"Saunders","year":"1971","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2008.10.017_bib28","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1016\/S0021-9258(18)62696-1","article-title":"Transformation of testosterone into 17 beta-hydroxy-5 alpha-androstan-3-one by microsomal preparations of human skin","volume":"245","author":"Voigt","year":"1970","journal-title":"J Biol Chem"},{"key":"10.1016\/j.contraception.2008.10.017_bib29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0303-7207(02)00377-5","article-title":"Evidence that chlormadinone acetate exhibits antiandrogenic activity in androgen-dependent cell line","volume":"198","author":"Terouanne","year":"2002","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.contraception.2008.10.017_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0010-7824(73)90004-8","article-title":"Disappearance of 1 alpha-3H-chlormadinone acetate from the plasma of women","volume":"7","author":"Dugwekar","year":"1973","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2008.10.017_bib31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0010-7824(70)90029-6","article-title":"Tissue localization of radioactive chlormadinone acetate and progesterone in the human","volume":"1","author":"Gallegos","year":"1970","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2008.10.017_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2515\/therapie:2003018","article-title":"The relative pharmacokinetics of two oral formulations of chlormadinone acetate: Luteran 5 mg and Luteran tablet 10 mg","volume":"58","author":"Chassard","year":"2003","journal-title":"Therapie"},{"key":"10.1016\/j.contraception.2008.10.017_bib33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0010-7824(73)90149-2","article-title":"Distribution of 1\u03b1-3H-chlormadinone acetate in the reproductive tract of women","volume":"4","author":"Dugwekar","year":"1973","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2008.10.017_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.contraception.2006.03.011","article-title":"Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate","volume":"74","author":"Terlinden","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2008.10.017_bib35","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1248\/cpb.25.2019","article-title":"Identification and anti-androgenic activity of the metabolites of 17alpha-acetoxy-6-chloropregna-4,6-diene-3,20-dione (chlormadinone acetate) in the rat, rabbit, dog and man","volume":"25","author":"Honma","year":"1977","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.contraception.2008.10.017_bib36","first-page":"9","article-title":"Pharmacology of progestogens. Basics aspects \u2014 progesterone derivates","volume":"6","author":"Kuhl","year":"2001","journal-title":"Menopause Review"},{"key":"10.1016\/j.contraception.2008.10.017_bib37","series-title":"Les Progestatifs","author":"Rozenbaum","year":"2002"},{"key":"10.1016\/j.contraception.2008.10.017_bib38","first-page":"131","article-title":"Contraception des femmes \u00e0 hauts risques vasculaires et m\u00e9taboliques: essai d'un d\u00e9riv\u00e9 de la 17 0H progest\u00e9rone","volume":"34","author":"Pelissier","year":"1983","journal-title":"Gyn\u00e9cologie"},{"key":"10.1016\/j.contraception.2008.10.017_bib39","first-page":"35","article-title":"The role of progesterone and progestins in hydroelectrolytic metabolism (author's transl)","volume":"9","author":"Elkik","year":"1980","journal-title":"Nouv Presse Med"},{"key":"10.1016\/j.contraception.2008.10.017_bib40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0015-0282(16)41654-7","article-title":"Lipid and carbohydrate metabolic studies after one year of megestrol acetate treatment","volume":"27","author":"Spellacy","year":"1976","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2008.10.017_bib41","series-title":"Progesterone and Progestins","first-page":"447","article-title":"The effects of progestins on coagulation","author":"Conard","year":"1983"},{"key":"10.1016\/j.contraception.2008.10.017_bib42","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0049-3848(80)90222-4","article-title":"At III content and antithrombin activity in oestrogen-progestogen and progestogen-only treated women","volume":"18","author":"Conard","year":"1980","journal-title":"Thromb Res"},{"key":"10.1016\/j.contraception.2008.10.017_bib43","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0002-9378(16)32486-3","article-title":"The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins","volume":"142","author":"Wynn","year":"1982","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2008.10.017_bib44","first-page":"45","article-title":"Progestogen contraception using chlormadinone acetate in women presenting high vascular risk. (A gynecoendocrine, metabolic and vascular study.)","volume":"15","author":"Pelissier","year":"1987","journal-title":"Contracept Fertil Sex (Paris)"},{"key":"10.1016\/j.contraception.2008.10.017_bib45","first-page":"79","article-title":"Administration prolong\u00e9e d'ac\u00e9tate de chlormadinone: effets m\u00e9taboliques, tensionnels et hormonaux","volume":"42","author":"Pelissier","year":"1991","journal-title":"Gyn\u00e9cologie"},{"key":"10.1016\/j.contraception.2008.10.017_bib46","first-page":"35","article-title":"Tol\u00e9rance clinique, m\u00e9tabolique et vasculaire de l'association 17\u03b2-estradiol et ac\u00e9tate de chlormadinone chez la femme m\u00e9nopaus\u00e9e normale ou \u00e0 risque art\u00e9riel. Etude prospective contr\u00f4l\u00e9e, randomis\u00e9e, \u00e0 long terme (18 mois)","volume":"29","author":"Pelissier","year":"1999","journal-title":"Rev Prat Gynecol Obstet"},{"key":"10.1016\/j.contraception.2008.10.017_bib47","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1471-0528.1987.tb02322.x","article-title":"Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary\u2013ovarian function in women","volume":"94","author":"Bazin","year":"1987","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2008.10.017_bib48","series-title":"The Physiology of Reproduction","first-page":"711","article-title":"The menstrual cycle and its neuroendocrine control","author":"Knobil","year":"1994"},{"key":"10.1016\/j.contraception.2008.10.017_bib49","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1210\/jc.81.12.4218","article-title":"The antigonadotropic activity of progestins (19-nortestosterone and 19-norprogesterone derivatives) is not mediated through the androgen receptor","volume":"81","author":"Couzinet","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.contraception.2008.10.017_bib50","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1210\/jc.84.11.4191","article-title":"The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women","volume":"84","author":"Couzinet","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.contraception.2008.10.017_bib51","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/(SICI)1096-9861(19960415)367:4<477::AID-CNE1>3.0.CO;2-1","article-title":"Progesterone receptor immunoreactivity in aromatic l-amino acid decarboxylase-containing neurons of the guinea pig hypothalamus and preoptic area","volume":"367","author":"Warembourg","year":"1996","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.contraception.2008.10.017_bib52","first-page":"37","article-title":"Antiovulatory action of chlormadinone acetate","volume":"22","author":"Pelissier","year":"1994","journal-title":"Contracept Fertil Sex (Paris)"},{"key":"10.1016\/j.contraception.2008.10.017_bib53","first-page":"33","article-title":"Activit\u00e9 antogonadotrope de l'ac\u00e9tate de chlormadinone","volume":"40","author":"Young","year":"2000","journal-title":"Rev Prat Gynecol Obstet"},{"key":"10.1016\/j.contraception.2008.10.017_bib54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.gyobfe.2004.12.002","article-title":"The antigonadotropic activity of chlormadinone acetate in reproductive women","volume":"33","author":"Chassard","year":"2005","journal-title":"Gynecol Obstet Fertil"},{"key":"10.1016\/j.contraception.2008.10.017_bib55","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.arcmed.2006.05.001","article-title":"A five-day gradual reduction regimen of chlormadinone reduces premenstrual anxiety and depression: a pilot study","volume":"37","author":"Contreras","year":"2006","journal-title":"Arch Med Res"},{"key":"10.1016\/j.contraception.2008.10.017_bib56","doi-asserted-by":"crossref","unstructured":"Cronje WH, Studd JW. Premenstrual syndrome and premenstrual dysphoric disorder. Prim Care 2002;29:1-12, v.","DOI":"10.1016\/S0095-4543(03)00070-8"},{"issue":"Suppl","key":"10.1016\/j.contraception.2008.10.017_bib57","first-page":"25","article-title":"The role of progestins in puberty and adolescence","volume":"119","author":"Druckmann","year":"1997","journal-title":"Zentralbl Gynakol"},{"key":"10.1016\/j.contraception.2008.10.017_bib58","series-title":"Practical Pediatric and Adolescent Gynecology","first-page":"144","article-title":"Menstrual disorders in the adolescent","author":"Dewhurst","year":"1980"},{"key":"10.1016\/j.contraception.2008.10.017_bib59","first-page":"CD004425","article-title":"Combined oral contraceptive pills for treatment of acne","author":"Arowojolu","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2008.10.017_bib60","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1080\/13697130400001307","article-title":"Role of progestins with partial antiandrogenic effects","volume":"7","author":"Sitruk-Ware","year":"2004","journal-title":"Climacteric"},{"key":"10.1016\/j.contraception.2008.10.017_bib61","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00044011-200222040-00002","article-title":"Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg\/ethinylestradiol 0.03 mg (Belara\u00ae). Results of a post-marketing surveillance study","volume":"22","author":"Schramm","year":"2002","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.contraception.2008.10.017_bib62","series-title":"Gyn\u00e4kologische Endokrinologie","author":"Runnebaum","year":"1994"},{"key":"10.1016\/j.contraception.2008.10.017_bib63","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.contraception.2004.07.009","article-title":"Progestogen-only contraception in women at high risk of venous thromboembolism","volume":"70","author":"Conard","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2008.10.017_bib64","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0010-7824(02)00536-X","article-title":"A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties","volume":"67","author":"Schramm","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2008.10.017_bib65","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(96)07496-X","article-title":"Population-based study of risk of venous thromboembolism associated with various oral contraceptives","volume":"349","author":"Farmer","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2008.10.017_bib66","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/01443619509015499","article-title":"The risk of thromboembolism associated with low-dose estrogen oral contraceptives","volume":"15","author":"Farmer","year":"1995","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2008.10.017_bib67","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/oxfordjournals.aje.a115799","article-title":"Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease","volume":"133","author":"Gerstmann","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.contraception.2008.10.017_bib68","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(95)91928-7","article-title":"Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components","volume":"346","author":"Jick","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2008.10.017_bib69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0010-7824(85)90114-3","article-title":"Pharmacokinetics of ethynyl estradiol: a current view","volume":"32","author":"Newburger","year":"1985","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2008.10.017_bib70","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0002-9378(87)90238-9","article-title":"Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone","volume":"156","author":"Jung-Hoffmann","year":"1987","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2008.10.017_bib71","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.contraception.2007.03.014","article-title":"Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study","volume":"76","author":"Schramm","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2008.10.017_bib72","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.contraception.2007.12.007","volume":"77","author":"Zahradnik","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2008.10.017_bib73","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0010-7824(98)00008-0","article-title":"Efficacy and safety of the new antiandrogenic oral contraceptive Belara","volume":"57","author":"Zahradnik","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2008.10.017_bib74","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/10401239309148824","article-title":"Women and mood disorders. Menarche to menopause","volume":"5","author":"Pariser","year":"1993","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.contraception.2008.10.017_bib75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0010-7824(01)00218-9","article-title":"A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation","volume":"64","author":"Sanders","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2008.10.017_bib76","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0306-4530(92)90058-F","article-title":"Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls","volume":"17","author":"Eriksson","year":"1992","journal-title":"Psychoneuroendocrinology"},{"issue":"Suppl 3","key":"10.1016\/j.contraception.2008.10.017_bib77","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0306-4530(03)00096-9","article-title":"A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder","volume":"28","author":"Rapkin","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.contraception.2008.10.017_bib78","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jsbmb.2004.02.003","article-title":"Comparative evaluation of androgen and progesterone receptor transcription selectivity indices of 19-nortestosterone-derived progestins","volume":"91","author":"Garcia-Becerra","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.contraception.2008.10.017_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00404-007-0497-z","article-title":"Depot-medroxyprogesterone acetate: an update","volume":"278","author":"Bakry","year":"2008","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.contraception.2008.10.017_bib80","first-page":"785","article-title":"Current concepts regarding use of DMPA","volume":"47","author":"Kaunitz","year":"2002","journal-title":"J Reprod Med"},{"key":"10.1016\/j.contraception.2008.10.017_bib81","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0020-7292(00)85324-2","article-title":"A survey of American women regarding the use of oral contraceptives and weight gain","volume":"70","author":"Wysocki","year":"2000","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.contraception.2008.10.017_bib82","first-page":"CD003987","article-title":"Combination contraceptives: effects on weight","author":"Gallo","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2008.10.017_bib83","first-page":"CD003987","article-title":"Combination contraceptives: effects on weight","author":"Gallo","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2008.10.017_bib84","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.contraception.2008.08.011","article-title":"The effects of two monophasic oral contraceptives containing 0.03 mg ethinylestradiol and either 2 mg chlormadinone acetate or 0.15 mg desogestrel on lipid, hormone and metabolic parameters","volume":"79","author":"Winkler","year":"2009","journal-title":"Contraception"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782408005489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782408005489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T04:46:06Z","timestamp":1632977166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782408005489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0010782408005489"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2008.10.017","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}